SOURCE: Cardima, Inc.

January 15, 2008 08:45 ET

Cardima Announces Appointment of Dr. Li Poa to Scientific Advisory Board as Surgical Consultant

FREMONT, CA--(Marketwire - January 15, 2008) - Cardima, Inc. (OTCBB: CADM) has announced the appointment of Dr. Li Poa to its Scientific Advisory Board as a Surgical Consultant. Dr. Poa is the Chief and Program Director of Cardiac Surgery at Stamford Hospital, Connecticut, a major teaching affiliate of the Columbia University College of Physicians and Surgeons where Dr. Poa is a faculty member.

An expert in modern cardiothoracic surgery, Dr. Poa has been providing critical physician input to Cardima on the development of its Surgical Ablation System. He has performed closed-chest endoscopic ablation procedures using Cardima's Surgical Ablation System. With extensive experience in new cardiac technologies, Dr. Poa is continuing his groundbreaking surgical techniques at Stamford Hospital.

Dr. Poa received his medical degree from Northwestern University Medical School in Chicago, completed his residency at Albert Einstein Medical Center in Philadelphia, and trained in Cardiothoracic Surgery at UCLA Medical Center in Los Angeles.

He is a member of many professional societies and advisory councils including the American Heart Association and Blue Shield's Health Advisory Board. He has been a co-chair of the President's National Health Advisory Board since 2001 and an Imperial Health Advisor for the Health Care Initiative and Counsel in Tokyo, Japan since 2005. An avid cyclist, he was a member of the U.S. Olympic Cycling team from 1982-84 and coached the U.S. National Track Cycling team in 1994.

In 1996, he was the first surgeon on the West Coast to introduce endoscopic vein harvesting. Dr. Poa's team developed and pioneered unilateral endoscopic ablation therapy for the treatment of atrial fibrillation ("AF") which has now been taught to over 120 medical centers worldwide. In 2002, his team became the first to perform endoscopic radial artery harvest for coronary artery bypass surgery in the western United States. In 2005, Dr. Poa's heart surgery team performed the first off-pump mitral valve repair (operating while the heart is beating) in the western states.

Dr. Poa is noted for his work in minimally invasive surgery to correct atrial fibrillation, a dangerous heartbeat irregularity that can lead to a higher propensity for strokes, which has drawn the interest of surgeons throughout the world. His team has traveled extensively on cardiac teaching tours in Europe and Asia. He has also established numerous cardiothoracic surgical programs throughout Asia. It is in this area that Cardima intends to focus its work with Dr. Poa.

In commenting on Dr. Poa's appointment to the Scientific Advisory Board, Cardima's CEO, Robert Cheney, said, "Dr. Poa is one of the most experienced physicians in the field of endoscopic ablation therapy. His knowledge and input will be invaluable to Cardima as we work together to make the Cardima Surgical Ablation System a valuable tool for surgeons around the world."

About Cardima

Cardima, Inc. has developed the PATHFINDER® and REVELATION® Series of diagnostic catheters, the INTELLITEMP® Energy Management Device, and the Surgical Ablation System (SAS). All of these devices are CE marked and received U.S. FDA 510(k) clearance. The REVELATION® Series of ablation catheters with the INTELLITEMP® EP Energy Management Device was developed and marketed for the treatment of atrial fibrillation (AF) after receiving CE mark approval in Europe; it is not currently available in the U.S.

For more information, please visit the Company's website at www.cardima.com.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those expressed in or implied by such forward-looking statements. Potential risks and uncertainties include: the uncertainties associated with the prospects for FDA approval of any new devices; the prospect for any future clinical trials or regulatory activities; the risk that the Company will not be able to raise additional capital in the immediate term as needed to continue operations and the risk that we will be unable to secure a strategic transaction involving the Surgical Ablation System. Additional risks and uncertainties are set forth in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006, the Company's Quarterly Report on Form 10-QSB for the third quarter ended September 30, 2007, and in the Company's subsequent SEC filings. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectations.

Contact Information